Engflag

Tramol

Quick links to important sections

Tramol

Tramol_DE

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tramol

Quick Facts

Property Description
Active Ingredients Paracetamol (Acetaminophen) and Tramadol hydrochloride
Form Tablet (Oral preparation)
Pharmacological Class Centrally acting analgesic; Combination opioid and non-opioid analgesic
Common Use Relief of moderate-to-severe pain
Origin Synthetic

Tramol: A Fixed-Dose Combination Analgesic

Tramol is a synthetic fixed-dose combination (FDC) analgesic designed for enhanced pain relief through a dual-action mechanism. It is formally categorized as a centrally acting analgesic because its primary function targets the processing of pain signals within the central nervous system. This drug entity, containing Paracetamol (Acetaminophen) and Tramadol hydrochloride, is a widely adopted formulation, with similar versions available under trade names such as Zaldiar and Ultracet.

The composition strategically combines a non-opioid analgesic with a synthetic opioid analgesic, establishing a multimodal approach to pain management. The combination of these two agents creates a synergistic analgesic effect. This means the medicine is clinically recognized to be more effective at managing pain when the components are combined than when either is used alone. The product is consistently manufactured as an oral tablet for systemic administration.

Composition and Multimodal Pain Strategy

The general purpose of Tramol is to provide potent relief for moderate-to-severe pain that has not been adequately addressed by simpler, single-component pain relievers. This enhanced capability stems directly from its synergistic action, a principle inherent to its pharmacological design.

This multimodal analgesia ensures that pain signals are interrupted through different chemical pathways simultaneously, achieving robust pain signal modulation. The dual mechanism targets different points in the pain pathway to address pain. The composition is specifically designed for situations requiring a comprehensive pain intervention, often used when managing complex, chronic pain conditions. The fixed-dose characteristic is a key differentiating factor, ensuring a standardized, reliable co-administration of both active ingredients.

Regulatory References

  1. Tramadol - StatPearls - NCBI Bookshelf
  2. Public Assessment Report UKPAR Tramadol hydrochloride/Paracetamol

What side effects are possible with Tramol?

Possible Side Effects and Safety Information

The official regulatory safety profile for this medicine is structured by the frequency and physiological system affected, based on data reported to health authorities like the EMA and FDA. Side effects are classified into categories that define their likelihood of occurrence.

Frequency-Classified Adverse Reactions

The most commonly documented adverse reactions primarily affect the central nervous system and the gastrointestinal tract, categorized as follows:

Classification Examples of Adverse Reactions
Very Common (ge 1/10) Nausea, Dizziness, Somnolence
Common (ge 1/100 to < 1/10) Vomiting, Constipation, Headache, Dry mouth, Confusion, Increased sweating
Uncommon (ge 1/1,000 to < 1/100) Hypertension, Tachycardia, Depression, Visual disturbances
Rare (ge 1/10,000 to < 1/1,000) Drug dependence, Convulsions, Loss of consciousness

Documented Serious Adverse Reactions and Constraints

The official labeling documents the potential for serious, low-frequency risks. These include the potential for Respiratory Depression, Serotonin Syndrome (particularly when used with other serotonergic agents), and the risk of severe Hepatic Failure associated with the paracetamol component. The combination product carries a defined risk of Drug Dependence and Abuse due to the opioid component, which increases with long-term exposure.

Usage constraints noted in regulatory documents include a formal contraindication in patients with severe hepatic impairment. Furthermore, adverse reactions such as dizziness and somnolence are often noted as more prevalent during the initiation of treatment.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of this fixed-dose combination involves the risk of dual component toxicity, as documented in official regulatory sources. The management of overdose requires specialized medical intervention.

Documented Manifestations and Severe Outcomes Manifestations may include central nervous system (CNS) depression (such as somnolence, stupor, and coma) and respiratory depression from the Tramadol component. Gastrointestinal symptoms like nausea and vomiting are also documented. Life-threatening outcomes include fatal respiratory failure, cardiovascular collapse, generalized seizures, and, critically, delayed hepatic necrosis and hepatic failure due to the Paracetamol component. Patients with pre-existing hepatic or renal impairment face an increased risk of severe toxicity.

Mandatory Emergency Action Immediate medical attention must be sought for any suspected overdose, even in the absence of initial symptoms. The official regulatory guidance requires individuals to contact emergency services immediately. This action is mandated due to the potential for delayed but severe complications, particularly liver damage.

Official Management Statements Management requires urgent symptomatic and supportive treatment and continuous hospital monitoring. N-acetylcysteine (NAC) is the indicated treatment for Paracetamol toxicity. Naloxone may be used to reverse respiratory depression caused by the opioid component.

Therapeutic Uses of Tramol

Tramol is used for managing symptomatic discomfort for patients experiencing moderate-to-severe pain that may be inadequately managed by single-agent pain relievers. The combination is relevant for easing distressing symptoms across different clinical contexts. This medication is relevant for easing acute pain when alternative treatments are inadequate.

Commonly, this drug is used for managing acute pain episodes, such as those that follow a procedure or injury, and it may be part of symptomatic management for certain conditions characterized by periods of heightened symptoms, including discomfort associated with osteoarthritis flares and low back pain.

“This medication is considered relevant for easing pain that is pronounced enough to require supportive symptom management from a combination analgesic.”

For these patients, the combination offers symptomatic relief that contributes to easing the overall symptom load and supports general well-being when symptoms interfere with routine activities.

Quick Fact: Relief for Moderate-to-Severe Pain
Primary Focus: Symptomatic relief for high-intensity pain.
Common Contexts: Postoperative recovery and chronic pain flare-ups.
Key Focus: Offers symptomatic relief when symptoms interfere with routine activities.

Regulatory References

  1. DailyMed drug label for Tramadol/Acetaminophen

Eligibility and Restrictions for Use

This section outlines the eligibility profile for tramadol based on official regulatory documents, detailing the specific populations and conditions for which use is restricted or prohibited.

Populations and Conditions for Whom Use is Contraindicated

Official labeling strictly prohibits the use of tramadol in the following groups:

  • Children younger than 12 years of age (absolute contraindication).
  • Patients younger than 18 years of age following surgical procedures involving the tonsils or adenoids.
  • Individuals with a history of hypersensitivity to tramadol, other opioids, or any component of the formulation.
  • Patients experiencing significant respiratory depression or acute, severe bronchial asthma.
  • Individuals with a known or suspected gastrointestinal obstruction (e.g., paralytic ileus).
  • Patients who are taking or have recently (within 14 days) taken a Monoamine Oxidase (MAO) inhibitor.
  • Individuals with acute intoxication from alcohol or other CNS depressants.

Use Requiring Restriction or Special Consideration

Caution, dose adjustment, or avoidance is mandated for certain populations:

  • Severe Organ Impairment: Patients with severe hepatic (liver) or renal (kidney) impairment often require increased dosing intervals or must avoid extended-release formulations.
  • Pregnancy and Lactation: Prolonged use during pregnancy can result in Neonatal Opioid Withdrawal Syndrome (NOWS). Use is not recommended while breastfeeding due to potential serious risk to the infant.
  • Age and Risk Factors: Use should be avoided in adolescents (12–18 years) with risk factors that increase sensitivity to respiratory depression (e.g., severe obesity, sleep apnea).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Tramol’s official interaction profile is defined by formal prohibitions, metabolic pathways, and pharmacodynamic risks documented in regulatory sources.

Formal Contraindications and Restrictions Co-administration is formally prohibited with Monoamine Oxidase Inhibitors (MAOIs), requiring a mandatory 14-day separation period following discontinuation of MAOI therapy. The medicine is also prohibited for use with any other products containing tramadol or acetaminophen. Severe hepatic impairment is a condition that formally contraindicates the use of this drug due to the acetaminophen component.

Pharmacodynamic Interactions The combination with other Central Nervous System (CNS) Depressants (including alcohol, sedatives, and anesthetics) carries a documented risk of profound sedation and respiratory depression. Concomitant use with Serotonergic Agents (such as SSRIs and TCAs) increases the regulatory-documented risk of Serotonin Syndrome and seizures. Mixed opioid agonists/antagonists may reduce the analgesic effect or precipitate withdrawal symptoms.

Metabolic and Exposure-Altering Interactions Interactions are documented involving CYP enzymes. The potent CYP3A4 inducer Carbamazepine significantly reduces the analgesic effect of Tramol and its co-administration is not recommended by regulatory authorities. Conversely, CYP2D6 inhibitors like Quinidine increase the plasma exposure of tramadol while decreasing the exposure of the active metabolite. Post-marketing surveillance also notes an alteration of the effect of Warfarin when co-administered. For patients with severe renal impairment, a specific restriction mandates that the dosage must not exceed two tablets every 12 hours.

Mechanism of Action

Tramol exerts its effects via a dual, complementary mechanism targeting the central nervous system. The parent compound, a racemic mixture, and its active metabolite, O-desmethyltramadol (M1), interact with multiple biological targets.

Opioid Receptor Agonism

Tramol and M1 function as agonists at the mu-opioid receptor (mu-OR). The binding of these molecules activates the G-protein coupled receptor, initiating an intracellular cascade that inhibits adenylyl cyclase activity. This leads to a decrease in intracellular cyclic AMP (cAMP) levels, resulting in the reduced release of pronociceptive neurotransmitters from primary afferent neurons in the spinal cord and supraspinal structures. M1 exhibits a significantly higher affinity for the mu-OR than the parent drug, contributing substantially to the overall effect.

Monoamine Reuptake Inhibition

Tramol also acts as a reuptake inhibitor of the monoamine neurotransmitters norepinephrine and serotonin at the synaptic cleft. This inhibitory action occurs through the blockade of the sodium-dependent norepinephrine transporter and the sodium-dependent serotonin transporter on the presynaptic membrane. The resultant increased concentration of norepinephrine and serotonin in the synaptic space enhances the activity of the descending inhibitory pain pathways originating in the brainstem, which modulate nociceptive signal transmission in the dorsal horn of the spinal cord. The combination of these two pathways—opioid receptor activation and monoamine reuptake inhibition—results in a systemic modulation of afferent nociceptive signaling.

Dosage and Administration Information

Official Administration Guidelines

Tramol is administered via the oral route as a fixed-dose combination tablet (37.5 mg tramadol hydrochloride and 325 mg acetaminophen). Usage is defined by specific dosage limits and procedural instructions.

Dosing and Frequency Patterns

The standard adult dosing regimen for pain relief starts with two tablets (75 mg tramadol / 650 mg acetaminophen). Dosing must be repeated only as needed for symptoms, adhering to a minimum interval of four to six hours between administrations.

Under no circumstances should the total dose exceed eight tablets in a 24-hour period, which is equivalent to 300 mg of tramadol and 2600 mg of acetaminophen. This medication is designated for short-term use, with treatment duration often limited to five days or less for the management of acute pain.

Administration and Population Adjustments

The tablets are to be swallowed whole with liquid and must not be crushed, split, or chewed. Administration may occur with or without food. A key instruction is to avoid taking the combination concurrently with any other medicinal products containing either acetaminophen or tramadol to prevent exceeding maximum dose ceilings.

Specific dosage modifications are required for certain populations. For patients with severe renal impairment (creatinine clearance < 30 mL/min), the maximum dose is restricted to two tablets every 12 hours. Use is generally not recommended in patients with severe hepatic impairment. If treatment is discontinued after a long period of use, a gradual downward taper is the appropriate procedural approach.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Tramol

Evidence for Use in Short-Term, Acute Pain

The primary research base for the combination of ingredients in Tramol comes from Randomized Controlled Trials (RCTs). These studies were used in research monitoring symptom evolution over time in populations experiencing temporary pain episodes, such as the discomfort that follows surgery or dental procedures. Research examined the drug's application in clinical trials involving adult patients during periods of increased symptom activity.

Studies reported measurements observed in the research related to symptom patterns over the short term, including patient-reported outcomes related to symptomatic experience and the monitoring of additional rescue medication use. Trial follow-up durations were limited, often lasting only a few days. Therefore, these short-term studies provide limited insight into sustained functional recovery or physical dependence factors that may emerge beyond the acute recovery phase.

Evidence for Use in Chronic Non-Cancer Pain

Research has also examined populations characterized by fluctuating or episodic manifestations, known as Chronic Non-Cancer Pain (CNCP). This evidence base incorporates a variety of research scenarios, including RCTs, Systematic Reviews, and observational settings evaluating daily-life functioning. Specific groups of adult patients with osteoarthritis flares and chronic low back pain were evaluated in these studies.

Research monitored outcomes reflecting daily functioning or activity level, such as disability scores, alongside pain intensity. Data show patterns related to patient-reported experiences, with some trials describing mixed patterns of symptom evolution across diverse patient groups. Trial follow-up durations were limited, as most controlled trials were structured to assess periods of up to 12 weeks, constraining the assessment of sustained long-term effects.

Key Studies & References

  1. A Systematic Review of Randomized Trials of Long-Term Opioid Management for Chronic Non-Cancer Pain
  2. Public Assessment Report UKPAR Tramadol hydrochloride/Paracetamol 37.5 mg/325 mg Film
  3. The use of tramadol for cancer-associated pain—a systematic review

Frequently Asked Questions (FAQ)

Common questions about Tramol (FAQ)

Q: Is Tramol an opioid, and how is its action different from non-opioid pain relievers like anti-inflammatories or aspirin?

A: Regulatory agencies classify Tramol as an opioid analgesic and a Schedule IV controlled substance due to its potential for misuse and dependence. Regulatory documents state that the medicine is indicated for the management of acute pain severe enough to require an opioid treatment. Its primary action involves activating opioid receptors and inhibiting the reuptake of neurotransmitters in the central nervous system. This distinct mechanism differs from non-opioid pain relievers like aspirin or anti-inflammatories.

Q: Why do doctors prescribe Tramol instead of other similar pain relievers?

A: Official documentation states that the medicine is indicated for the management of acute pain severe enough to require an opioid treatment. It is used in situations where alternative treatment options, such as non-opioid analgesics, have not been tolerated or are considered inadequate to manage symptoms.

Q: Does Tramol make you feel sleepy or tired during the day?

A: Yes, official regulatory documents list drowsiness, tiredness, and sleepiness (somnolence) as possible side effects associated with the use of the medicine. These effects relate to its action on the central nervous system.

Q: How quickly should I expect to feel the effect of Tramol?

A: Pharmacokinetic data cited in official product information indicates that the onset of analgesic effects is typically observed in less than 1 hour after the oral administration of the medicine.

Q: Is it common for people to get headaches when starting Tramol?

A: Headache is listed as a possible side effect of the medicine in official documentation. It is part of the recognized range of adverse effects that may be associated with treatment.

Q: Does Tramol interact with common vitamins or supplements?

A: Official interaction information focuses on prescription drugs and certain supplements that affect the serotonin system (e.g., Tryptophan). Regulatory bodies provide information advising that patients inform their healthcare provider about all prescription, over-the-counter, and herbal products used.

Q: What happens if a dose of Tramol is missed?

A: Official patient information states that the appropriate procedure for a missed dose is to skip the missed dose and take the next dose at the usual scheduled time. It is advised to avoid taking two doses to make up for a missed dose.

Q: Is Tramol considered a strong pain medication?

A: Official regulatory documents indicate that the medicine is used for the treatment of acute pain severe enough to require an opioid treatment. Tramadol is classified by regulatory agencies as an opioid analgesic.

Q: Can older adults safely use Tramol?

A: Official warnings note that elderly patients may be more sensitive to the effects of pain medicines. They are documented as being at an increased risk for opioid-related adverse effects such as respiratory depression and sedation. Dosage adjustments are often required for conditions common in older adults, such as renal impairment.

Q: Are there any long-term effects described for Tramol?

A: The medicine is generally designated for short-term use (e.g., up to five days for acute pain). Research evidence on sustained long-term effects, functional improvement, or drug dependence beyond short-term trials is documented as limited or insufficient for comprehensive assessment.

Q: Does Tramol affect driving ability according to official information?

A: Official patient warnings note that due to the potential for sleepiness, dizziness, or lightheadedness, individuals should avoid driving or operating heavy machinery until they know how the medicine affects them.

Q: What is the official purpose of Tramol?

A: The medicine is officially indicated for the management of acute pain that is severe enough to require an opioid treatment and for which alternative treatments are inadequate.

Q: Is Tramol commonly used for back pain or muscle aches?

A: Research and clinical trials cited in official sources have examined the use of the medicine in specific conditions such as chronic low back pain and pain related to osteoarthritis flares.

Q: Why are there different strengths or forms of Tramol available?

A: Official documentation notes that different formulations, such as immediate-release or extended-release, are developed for different therapeutic goals. These variations are intended to manage either short-term acute pain or chronic, ongoing pain that requires round-the-clock treatment.

Q: Is it possible to become physically dependent on Tramol?

A: Official documents state that with prolonged or repeated use, the medicine may cause physical dependence. A gradual downward taper is stipulated in official guidelines as the procedural approach when stopping treatment after long-term use.

Q: Are there specific groups of people who should not use Tramol?

A: Yes, official documentation lists specific situations where the medicine is formally contraindicated. These include individuals with severe hepatic impairment (liver failure), those taking MAO Inhibitors, and children younger than 12 years of age.

Q: Can Tramol be used by people with a history of stomach problems?

A: Regulatory warnings note that the medicine's use is subject to caution in patients with a history of certain severe stomach or bowel problems. The presence of conditions such as paralytic ileus or stricture can be a specific concern.

Q: Is it true that Tramol can cause dizziness?

A: Yes, dizziness is listed as a possible side effect of the medicine in official documentation. This is due to its effects on the central nervous system.

Q: Do official documents mention Tramol affecting mood?

A: The medicine's mechanism involves increasing concentrations of serotonin and norepinephrine, which are brain chemicals associated with mood. Documented risks include Serotonin Syndrome, and certain mental changes, such as mental confusion, are listed as potential side effects.

Q: Is it important to take Tramol at the exact same time every day?

A: Official guidelines state the medicine should be taken as needed for pain relief (PRN), adhering to a minimum dose interval. This approach indicates that it is not necessarily a medicine that must be taken at the exact same time every day, but rather based on symptom management.

Q: What is the difference between immediate-release and extended-release Tramol?

A: Immediate-release versions are typically used for acute pain as needed, while official documentation notes that extended-release formulations are intended for the management of chronic, ongoing pain. Extended-release versions are generally taken once daily to maintain consistent pain relief over a longer period.

Q: What is the typical age range of people who use Tramol?

A: The medicine is indicated for use in adults and is contraindicated in children younger than 12 years of age. Dosing and safety information typically focuses on adult populations.

Q: Why do some people say Tramol helps them sleep?

A: Official warnings list sleepiness (somnolence) and sedation as known side effects of the medicine. These effects on the central nervous system may contribute to a perceived aid for sleep in some users.

Q: Can taking Tramol affect laboratory test results?

A: Official documentation requires that during treatment, the doctor check the patient's progress at regular visits. Blood and urine tests may be needed to check for any unwanted effects caused by the medicine.

Q: Is Tramol effective for nerve pain?

A: Clinical research cited in official sources has examined populations characterized by fluctuating or episodic symptoms, including conditions like chronic low back pain, which may have nerve pain components. However, official regulatory bodies do not specify 'neuropathic pain' as a formal indication for the medicine.

Q: Are there any known issues with Tramol and caffeine?

A: Official warnings focus primarily on other CNS depressants and serotonergic agents, which pose documented risks. Patients are generally advised in patient guides to discuss the use of all concomitant substances, including stimulants like caffeine, with a healthcare provider.

Q: What should a patient know before starting Tramol, according to regulatory bodies?

A: Regulatory bodies provide comprehensive patient information (Medication Guides) detailing key warnings that must be understood. This includes the risks of misuse, respiratory depression, specific contraindications, common side effects, and administration rules.

Q: Can Tramol be used in children, according to official guidelines?

A: No. Official guidelines contraindicate the use of the medicine in children younger than 12 years of age for any indication. Additional warnings also apply to adolescents (12-18) following certain surgical procedures.

Q: What are the official warnings about allergic reactions to Tramol?

A: Official documentation warns of the possibility of a serious allergic reaction. Signs of a serious allergic reaction, such as a severe rash or trouble breathing, require immediate emergency medical attention.

How should Tramol be stored and disposed of?

How to Store and Dispose of Tramol?

The storage and disposal of Tramol (Tramadol/Paracetamol) are strictly defined by regulatory requirements to ensure product stability and prevent accidental exposure.

Storage Requirements

Tramol tablets must be stored at controlled room temperature, typically between 20 C and 25 C. Official labeling requires the medication to be stored away from light and moisture and mandates that the product must not be frozen. To maintain drug integrity, the tablets should remain in their original, closed container.

Child Safety

Due to the risks associated with the opioid component, it is mandatory to store Tramol securely and out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Tramol must be disposed of properly according to local guidelines. The official methods for discarding this product are primarily through a drug take-back program. If a take-back option is unavailable, the tablets should be immediately flushed down the toilet as specified by regulatory guidance for certain high-risk medicines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Tramol found in:

A-Z Index: